NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

NeuroSense Therapeutics and Genetika+ collaborate in a precision medicine initiative focusing on Alzheimer's Disease. The partnership aims to enhance drug development by utilizing advanced technology for patient-specific neuronal analysis. NeuroSense's innovative PrimeC therapy targets multiple disease-related pathologies, offering a promising approach to AD treatment. The ongoing Phase 2 clinical trial at Rambam Health Care Campus will evaluate PrimeC's therapeutic potential in mild to moderate AD patients over 12 months.

Medical Research Analyst

The partnership between NeuroSense and Genetika+ marks a notable advance in the pursuit of treatment for Alzheimer's Disease (AD), a field fraught with high-profile disappointments. The application of Genetika+'s precision medicine technologies offers a targeted approach to drug development. By analyzing drug-induced changes on a cellular level using patients' derived neurons, it's feasible we could see a more sophisticated understanding of drug mechanisms and patient responses. The potential for this collaboration to enhance understanding of AD pathophysiology and improve the drug development pipeline is significant. For investors, these developments may portend long-term value creation if the technologies lead to a marketable, effective treatment for AD, a market that is currently underserved and has a high unmet clinical need.

Biotech Financial Analyst

The strategic collaboration between NeuroSense and Genetika+ is financially significant due to the potential of PrimeC therapy. The robust design of the Phase 2 clinical trial and the focus on mild to moderate non-familial AD could position the drug as a candidate for a wider patient demographic. The move to incorporate biomarkers and plasma plus cerebrospinal fluid analysis into the trial endpoints indicates a commitment to demonstrating both safety and efficacy, which could be compelling to regulatory agencies and investors alike. A successful trial could lead to significant stock appreciation, given the high demand for effective AD treatments and the current absence of a dominant market player. For investors, monitoring the progression of this trial will be key, as positive results could provide a catalyst for stock growth and position NeuroSense as a leading innovator in AD treatment.

Market Research Analyst

PrimeC's unique, multi-target approach that diverges from conventional amyloid-beta-centric therapies represents a disruptive potential in the AD treatment market. Diversification of therapeutic targets within a single drug could resonate well with clinicians who are managing complex AD cases. By leveraging Genetika+'s technology for personalized treatment, NeuroSense could address a growing demand for customized healthcare solutions. In terms of market trends, there's a clear shift towards precision medicine and treatments with strong safety profiles. The commercial success of PrimeC, should it prove effective, may redefine market standards for AD therapies. For investors, the dual focus on efficacy and safety, combined with precision medicine, may suggest a lucrative opportunity in a future market poised for growth, driven by a globally aging population.

CAMBRIDGE, Mass., April 22, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing novel treatments for severe neurodegenerative diseases announced today a collaboration in Alzheimer's Disease (AD) drug development with Genetika+, a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense's currently ongoing Phase 2 AD clinical trial, leverages Genetika+'s state-of-the-art technology that derives frontal cortex neurons from individual patients' blood to quantify drug-induced neuronal plasticity in vitro.

The Genetika+ technology serves as a human AD disease model and will be used to correlate clinical response with cellular effects, for mechanistic drug insights and patient subset identification, supporting drug development and potentially commercialization. This collaboration addresses key challenges in the development of drugs for AD, by promoting disease and drug mechanistic understanding, increasing the likelihood of success of AD drug development, and enabling the realization of precision medicine approaches. 

"We believe Genetika+'s technology presents a unique opportunity to optimize our current ongoing trial. It harmonizes seamlessly with our evaluation of our combination drug therapy through clinical assessments and an extensive array of biomarkers," stated Dr. Shiran Zimri, VP of R&D at NeuroSense. "There are significant opportunities to harness cutting-edge advancements in AD therapeutic research and these are crucial for the future of early detection and treatment of neurodegenerative conditions."

Distinguished by its innovative approach, NeuroSense's PrimeC therapy stands out in the landscape of AD treatments. Unlike conventional methods that predominantly target amyloid-beta (Aβ), PrimeC adopts a multi-targeted strategy, concurrently addressing Aβ aggregation, TDP-43, and other key disease-related pathologies. This unique approach not only diversifies the therapeutic targets but also offers the potential for more potent treatment outcomes. With a well demonstrated synergistic mode of action, compelling pre-clinical and clinical data in related filed, and a strong safety profile, PrimeC is poised to potentially provide therapeutic efficacy in AD.

"This partnership represents a critical step forward in the fight against Alzheimer's Disease," said Daphna Laifenfeld, co-founder and CSO at Genetika+. "By combining our leading-edge technologies, we anticipate the possibility of both bring efficacious therapies to patients sooner, and to moving beyond a one-size-fits-all approach to AD treatment and unlock the potential for personalized, targeted therapies that significantly improve patient outcomes."

Currently enrolling at the Stroke and Cognition Institute, Rambam Health Care Campus, Haifa, Israel, RoAD, NeuroSense's Phase 2 randomized, prospective double-blind, placebo-controlled study is designed to evaluate the therapeutic potential of PrimeC in treating AD. The study will consist of 20 patients with mild to moderate non-familial AD. Participants will receive PrimeC or placebo (1:1) twice daily for 12 months and will be evaluated every three months. Endpoints include clinical outcome measurements, AD-related biomarkers, and markers of target engagement extracted from plasma and cerebrospinal fluid (CSF). The study is expected to reveal the safety of PrimeC in AD, as well as shed light on the efficacy and biological activity of this combination therapy in this indication.

About Genetika+

Genetika+, founded in 2018 by Talia Cohen-Solal, Ph.D., and Daphna Laifenfeld, Ph.D., is developing personalized medicine solutions to optimize treatment for psychiatric and neurological diseases. The company's proprietary AI-powered platform, Stemifai, leverages stem cell differentiation and machine learning to inform and advance CNS drug development processes. To learn more, follow us on LinkedIn or on Twitter @Genetikaplus.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, please visit the Company's website and follow NeuroSense on LinkedIn and X (Twitter).

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding NeuroSense's collaboration with Genetika+, and the timing and results of a Phase 2 trial for Alzheimer's disease. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the risk that NeuroSense's collaboration with Genetika+ will not bring the anticipated benefits, unexpected R&D costs or operating expenses, the timing of expected regulatory and business milestones, a delay in patient enrollment for, and unanticipated results of, a Phase 2 trial for Alzheimer's disease; the potential for PrimeC to safely and effectively target AD; preclinical and clinical data for PrimeC; the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data; the development and commercial potential of any product candidates of the company; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 4, 2024. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense Therapeutics Ltd. undertakes no duty to update such information except as required under applicable law.

Logo : https://mma.prnewswire.com/media/2386697/NRSN_GNTC_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurosense-and-genetika-initiate-precision-medicine-collaboration-beginning-with-ongoing-phase-2-clinical-trial-in-alzheimers-disease-302122778.html

SOURCE NeuroSense

FAQ

What collaboration was announced by NeuroSense Therapeutics with Genetika+?

NeuroSense Therapeutics announced a collaboration with Genetika+ in Alzheimer's Disease drug development.

What technology is being leveraged in the collaboration?

The collaboration leverages Genetika+'s technology that derives frontal cortex neurons from individual patients' blood to quantify drug-induced neuronal plasticity.

What is the objective of the collaboration in the ongoing Phase 2 clinical trial?

The collaboration aims to correlate clinical response with cellular effects using Genetika+'s technology to support drug development and potentially commercialization.

What is unique about NeuroSense's PrimeC therapy for Alzheimer's Disease?

PrimeC therapy adopts a multi-targeted strategy addressing Aβ aggregation, TDP-43, and other key disease-related pathologies, offering potential for more potent treatment outcomes.

Where is the Phase 2 clinical trial for PrimeC therapy being conducted?

The Phase 2 clinical trial for PrimeC therapy is currently enrolling at the Stroke and Cognition Institute, Rambam Health Care Campus, Haifa, Israel.